⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290730 | 0.93 | — | — | |
| SCHEMBL27269513 | 0.90 | — | — | |
| SCHEMBL2290838 | 0.90 | — | — | |
| SCHEMBL18782433 | 0.86 | KDM4E (0.31) | — | |
| SCHEMBL2294031 | 0.85 | — | — | |
| SCHEMBL25046568 | 0.80 | CXCR4 (0.33) | — | |
| SCHEMBL14546631 | 0.78 | — | — | |
| SCHEMBL21182820 | 0.76 | — | — | |
| SCHEMBL19983270 | 0.72 | KDM4E (0.36) | — | |
| SCHEMBL24820630 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150374-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022268152-A1 | GLP-1 RECEPTOR AGONIST AND COMPOSITION AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022068849-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEIGENE, LTD. (KY) | 2022-04-07 | — | — | WO | disclosed |
| WO-2021180235-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | 四川海思科制药有限公司 | 2021-09-16 | — | — | WO | disclosed |
| EP-2897942-B1 | FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9427442-B2 | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9249157-B2 | Tricyclic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006716-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006064286-A1 | CATHEPSIN S INHIBITORS | MEDIVIR UK LTD (GB) | 2006-06-22 | — | — | WO | disclosed |
| EP-1019022-A1 | PERFORATED MICROPARTICLES AND METHODS OF USE | Inhale Therapeutic Systems, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999016419-A1 | PERFORATED MICROPARTICLES AND METHODS OF USE | INHALE THERAPEUTIC SYSTEMS, INC. (US) | 1999-04-08 | — | — | WO | disclosed |